Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
UNICHEMLAB.NS
Strong BuyFull HouseUnichem Laboratories Limited · Healthcare · India · $413M · Avg Vol: $2M/d
87
StockRankGet insider-trade alerts
Q
61
V
52
M
72
P/E (TTM)
12.6x
ROE
9.3%
D/E
0.2x
Dividend %
—
COMPANY DESCRIPTION
Unichem Laboratories Limited, a pharmaceutical company, manufactures and sells pharmaceutical products in Asia, Europe, Africa, CIS, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 13.0B | 17.4B | 20.6B | 21.6B | 18.4% | 23.1B |
| EPS (INR) | -28.72 | -13.32 | 19.53 | 35.91 | 83.9% | 43.24 |
| Shares | 70.4M | 70.4M | 70.4M | 70.4M | 0.0% | 70.4M |
| Debt | 3.1B | 2.5B | 4.6B | 5.0B | 16.8% | 5.0B |
| Equity | 24.4B | 24.4B | 24.5B | 27.2B | 3.7% | — |
| Op CF | -850.9M | 140.0M | -70.2M | 36.4M | -49.0% | 36.4M |
| Inv CF | 2.0B | 504.0M | -2.4B | 1.9B | — | — |
| Fin CF | -813.0M | -1.1B | 1.8B | 18.6M | — | — |
Loading 1Y...
PRICE (1Y)+3.6%
SMA 50SMA 200
Close
$5.71
RSI (14)
58.6
52W High
$7.23
From 52W High
0.8%
SCORE BREAKDOWN
Quality
61
ROIC
13.4%79.4
ROE
9.3%68.1
GP/Assets
31.3%65.7
Op. Margin
6.3%55.2
FCF/Assets
-3.2%38.5
Piotroski
668.8
Int. Cover
12.1x64.7
D/E Ratio
0.18x51.5
Current Ratio
2.48x47.8
Value
52
P/E (TTM)
12.6x81.7
EV/EBITDA
17.9x39.5
P/FCF
—N/A
P/B
1.4x75.5
P/S
1.7x73.4
Div Yield
—N/A
Momentum
72
52W High %
79%64.8
RS 6M
68%93.7
SMA 50/200
1.27x91.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$413M
P/E (Forward)
—
Gross Margin
50.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UNICHEMLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UNICHEMLAB.NS | Unichem Laboratories Limited(you) | $413M | 87 | Strong Buy |
| AARTIDRUGS.NS | Aarti Drugs Limited | $406M | 80 | Strong Buy |
| INDSWFTLAB.NS | Ind-Swift Laboratories Limited | $356M | 81 | Strong Buy |
| SOLARA.NS | Solara Active Pharma Sciences Limited | $357M | 81 | Strong Buy |
| IOLCP.NS | IOL Chemicals and Pharmaceuticals Limited | $653M | 89 | Strong Buy |
| RPGLIFE.NS | RPG Life Sciences Limited | $489M | 79 | Buy |
| MOREPENLAB.NS | Morepen Laboratories Limited | $677M | 85 | Strong Buy |
| SPARC.NS | Sun Pharma Advanced Research Company Limited | $696M | 89 | Strong Buy |
| WINDLAS.NS | Windlas Biotech Limited | $248M | 84 | Strong Buy |
| BLISSGVS.NS | Bliss GVS Pharma Limited | $810M | 87 | Strong Buy |
Peer medians: ROE 11.9% · P/E 42.8x · Gross margin 59.4%